Quantitative metabolomics services for biomarker discovery and validation.
Specializing in ready to use metabolomics kits.
Your source for quantitative metabolomics technologies and bioinformatics.
Loader

Filter by Pathway Type:



Showing 123291 - 123300 of 605359 pathways
SMPDB ID Pathway Name and Description Pathway Class Chemical Compounds Proteins

SMP0130870

Pw132538 View Pathway

Indocyanine green acid form Drug Metabolism

Indocyanine green acid form is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Indocyanine green acid form passes through the liver and is then excreted from the body mainly through the kidney.
Metabolic
  • Indocyanine green acid form

SMP0144452

Pw146120 View Pathway

Indocyanine green acid form Drug Metabolism Action Pathway

Drug Action
  • Indocyanine green acid form

SMP0130714

Pw132382 View Pathway

Indocyanine green Drug Metabolism

Indocyanine green is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Indocyanine green passes through the liver and is then excreted from the body mainly through the kidney.
Metabolic
  • Indocyanine green

SMP0145285

Pw146953 View Pathway

Indocyanine green Drug Metabolism Action Pathway

Drug Action
  • Indocyanine green

SMP0125880

Missing View Pathway

Indole pyruvate decomposition

Metabolic

SMP0000104

Pw000260 View Pathway

Indomethacin Action Pathway

Indomethacin (also named Amuno or Indocid) is a nonsteroidal anti-inflammatory drug (NSAID). It can be used to treat prostaglandin G/H synthase related fever, swelling, pain and inflammation. Indomethacin can block prostaglandin synthesis by the action of inhibition of prostaglandin G/H synthase 1 and 2. Prostaglandin G/H synthase 1 and 2 catalyze the arachidonic acid to prostaglandin G2, and also catalyze prostaglandin G2 to prostaglandin H2 in the metabolism pathway. Decreased prostaglandin synthesis is caused by presence of indomethacin.
Drug Action

SMP0142787

Pw144455 View Pathway

Indomethacin Drug Metabolism Action Pathway

Drug Action

SMP0124592

Pw126075 View Pathway

Indomethacin NSAID Action Pathway

Indomethacin is a nonsteroidal anti-inflammatory (NSAID) used for symptomatic management of chronic musculoskeletal pain conditions and to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants. It has analgesic, antipyretic and anti-inflammatory effects. It targets the prostaglandin G/H synthase-1 (COX-1) and prostaglandin G/H synthase-2 (COX-2) in the cyclooxygenase pathway. The cyclooxygenase pathway begins in the cytosol with phospholipids being converted into arachidonic acid by the action of phospholipase A2. The rest of the pathway occurs on the endoplasmic reticulum membrane, where prostaglandin G/H synthase 1 & 2 converts arachidonic acid into prostaglandin H2. Prostaglandin H2 can either be converted into thromboxane A2 via thromboxane A synthase, prostacyclin/prostaglandin I2 via prostacyclin synthase or prostaglandin E2 via prostaglandin E synthase. COX-2 is an inducible enzyme, and during inflammation, it is responsible for prostaglandin synthesis. It leads to the formation of prostaglandin E2 which is responsible for contributing to the inflammatory response by activating immune cells and for increasing pain sensation by acting on pain fibers. Indomethacin inhibits the action of COX-1 and COX-2 on the endoplasmic reticulum membrane. This reduces the formation of prostaglandin H2 and therefore, prostaglandin E2 (PGE2). The low concentration of prostaglandin E2 attenuates the effect it has on stimulating immune cells and pain fibers, consequently reducing inflammation and pain. Fever is triggered by inflammatory and infectious diseases. Cytokines are produced in the central nervous system (CNS) during an inflammatory response. These cytokines induce COX-2 production that increases the synthesis of prostaglandin, specifically prostaglandin E2 which adjusts hypothalamic temperature control by increasing heat production. Because indomethacin decrease PGE2 in the CNS, it has an antipyretic effect.
Drug Action

SMP0174401

Missing View Pathway

Indomethacin Predicted Metabolism Pathway new

Metabolites of Indomethacin are predicted with biotransformer.
Metabolic

SMP0144238

Pw145906 View Pathway

Indoramin Drug Metabolism Action Pathway

Drug Action
  • Indoramin
Showing 123291 - 123300 of 131501 pathways